Now showing items 1-3 of 3

    • The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. 

      Gengiah, Tanuja N.; Holford, Nicholas H. G.; Botha, Julia H.; Gray, Andrew L.; Naidoo, Kogieleum.; Abdool Karim, Salim Safurdeen. (Springer-Verlag., 2011)
      Purpose: Drug interactions are of concern when treating patients co-infected with human immunodeficiency virus (HIV) and tuberculosis. Concomitant use of efavirenz (EFV) with the enzyme inducer rifampicin might be expected ...
    • Initiating antiretrovirals during tuberculosis treatment: a drug safety review. 

      Gengiah, Tanuja N.; Gray, Andrew L.; Naidoo, Kogieleum.; Abdool Karim, Quarraisha. (Informa UK, Ltd., 2011)
      Introduction: Integrating HIV and tuberculosis (TB) treatment can reduce mortality substantially. Practical barriers to treatment integration still exist and include safety concerns related to concomitant drug use because ...
    • Integration of antiretroviral therapy with tuberculosis treatment. 

      Abdool Karim, Salim Safurdeen.; Naidoo, Kogieleum.; Grobler, Anneke.; Padayatchi, Nesri.; Baxter, Cheryl.; Gray, Andrew L.; Gengiah, Tanuja N.; Gengiah, Santhanalakshmi.; Naidoo, Anushka.; Jithoo, Niraksha.; Nair, Gonasagrie.; El-Sadr, Wafaa.; Friedland, Gerald H.; Abdool Karim, Quarraisha. (Massachusetts Medical Society., 2011-10-20)
      Background. We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains ...